DERM has been increasing steadily in price recently and seem to have good momentum going into their next reporting period.
The firm is also is a high squeeze territory with 15% float in May alone!
If a squeeze does/doesnt happen there is also room for a larger pharma player to acquire which would likely be of interest to Fortress (largest shareholder with 34%) since this is likely the only way to materialize their return. this would be a premium to all equity holders!
all in: two solid levers for equity appreciation 😎🔥